SpringWorks Therapeutics Inc.

After a couple of months of talks, Merck KGaA has inked a deal to buy SpringWorks Therapeutics which will expand its presence in the US and sharpen the firm’s focus in rare diseases and cancer. The pu

Merck KGaA only has two-late stage candidates in its pipeline but CEO Belén Garijo has told Scrip that the German company is laser-focused on adding more assets. Speaking at Merck’s annual press con

SpringWorks Therapeutics has received US approval for its second commercial product just a day after Merck KGaA confirmed rumors that it was in advanced negotiations to acquire the US biotech. SpringW

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. B+L Bolsters Ophthalmology With Acquis